Sign in
CompletedPhase 4

Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures

Key facts

Who runs it
The University of Hong Kong
Where
Hong Kong1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
977 people enrolled
Started
5 Oct 2020
Ended
31 Dec 2025
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • FluBlok
  • Placebo
Record updated
15 May 2026

Who can take part

Age
18 years to 45 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Aged 18-45 years at enrolment
  • Capable of providing informed consent
  • Resident in Hong Kong in the coming 2 years

Who cannot take part

  • Currently taking medication for any condition that impairs immune system
  • Individuals who report medical conditions not suitable to receive inactivated influenza vaccines, such as: Severe allergic reaction (e.g., anaphylaxis) after previous dose of any influenza vaccine; or to a vaccine component; moderate or severe acute illness with or without fever after any previous influenza vaccination; or a history of Guillain-Barré syndrome (GBS) within 6 weeks of previous influenza vaccination
  • Included in one of the priority groups to receive influenza vaccination in Hong Kong (priority groups include pregnant women, long-stay residents of institutions for persons with disability, persons with chronic medical problems (chronic cardiovascular, lung, metabolic or kidney diseases, obesity (body mass index 30 or above) and chronic neurological condition), healthcare workers or persons working in poultry, pig farming or pig slaughtering industry)
  • With diagnosed medical conditions related to their immune system
  • Individuals, who report medical conditions not suitable to receive intramuscular injection, such as bleeding disorders; habitually taking anticoagulants (with the exception of antiplatelets such as aspirin)
  • Individuals who have any medical conditions not suitable to receive inactivated influenza vaccines as determined by a clinician
  • Vaccinated against influenza in the past 24 months

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The aims of this vaccine trial are: (1) to measure humoral and selected cellular immune responses to repeated influenza vaccination with Flublok, including these responses' associations with age, birth year, and prior vaccination history; (2) to identify the characteristics of study participants who are vaccinated but still become infected with influenza virus ("vaccine failures") and participants who have poor immune responses to vaccination; and (3) to predict how influenza vaccinations and infections shape immunity.

The 2 groups in the trial

  • Influenza vaccinationTreatment being tested

    Treatment: FluBlok

  • PlaceboPlacebo, for comparison

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE) Study - a Randomized Controlled Trial
Publications
Record updated
15 May 2026